Owkin

Owkin was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher at the E?cole Normale Supe?rieure, and a Stanford University PostDoc. Owkin is a French-American startup that deploys AI and Federated Learning for medical research. Our mission is to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. Our latest projects include: Mesothelioma research with Centre Léon Bérard published in Nature Medicine (https://www.nature.com/articles/s41591-019-0583-3) and the COVID-19 AI Consortium (https://owkin.com/covid-19/) to bring breakthrough medical discoveries and actionable findings to the fight against the Covid-19 pandemic. Our data scientists are among the best in the world, with several Kaggle Masters, DREAM Challenge top performers, and publications in Nature Medicine, ICML, NIPS and other top scientific journals. Owkin is backed by renowned investors — such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital — as well as a distinguished scientific board. To build this vision, Owkin is growing rapidly, with offices located in the USA, France, and the UK. We have complimentary beverages, snacks, and fruit, nerf guns, foosball and other goodies essential to the smooth running of a startup!